Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20,788,527
-
Total 13F shares
-
123,832,570
-
Share change
-
-9,032,829
-
Total reported value
-
$84,191,630
-
Put/Call ratio
-
5.5%
-
Price per share
-
$0.68
-
Number of holders
-
156
-
Value change
-
-$9,619,003
-
Number of buys
-
72
-
Number of sells
-
63
Institutional Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q1 2025
As of 31 Mar 2025,
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) was held by
156 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
123,832,570 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, Nantahala Capital Management, LLC, ACADIAN ASSET MANAGEMENT LLC, EVENTIDE ASSET MANAGEMENT, LLC, PRIMECAP MANAGEMENT CO/CA/, RENAISSANCE TECHNOLOGIES LLC, Almitas Capital LLC, GEODE CAPITAL MANAGEMENT, LLC, and TCG Crossover Management, LLC.
This page lists
156
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.